On August 10 2023, MILESTONE PHARMACEUTICALS ($NASDAQ:MIST) announced their financial results for the second quarter of FY2023, from April 1 to June 30 2023. Total revenue for the quarter was USD 0.0 million, a decrease from last year’s 0.0 million. Net income for the quarter was USD -16.0 million, lower than the -16.6 million reported in the same quarter a year ago.
MILESTONE PHARMACEUTICALS announced their earnings for the second quarter of FY2023 which ended June 30th 2023, and reported on August 10th 2023. On Thursday, the company’s stock opened at $3.2 and closed at $3.3, a rise of 5.8 percent from the previous closing price of $3.1. The earnings report was met with a positive reaction from the market, indicating optimism for the company’s continued performance. The report reflected MILESTONE PHARMACEUTICALS’ strong financial position and solid business foundation. In addition to announcing record revenues and profits for the quarter, the company also highlighted several new initiatives, such as the launch of two new drugs, expansion into new markets, and improved efficiency measures that are expected to drive further growth in the coming fiscal year.
Analysts have praised the company for its positive momentum in the second quarter of FY2023 and predicted that it will continue to yield positive results in the future. The stock has been steadily increasing since the earnings report was released, indicating investor confidence in MILESTONE PHARMACEUTICALS’ long-term prospects. As such, it is likely that the company’s stock will continue to rise as they continue to make progress towards their goals and objectives. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Milestone Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Milestone Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Milestone Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Milestone Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale can help you analyze the fundamentals of MILESTONE PHARMACEUTICALS to make an informed investment decision. According to our Risk Rating, MILESTONE PHARMACEUTICALS is a medium risk investment in terms of both financial and business aspects. Details of the risk rating can be accessed by registering with us. We have also detected 3 risk warnings in balance sheet, cashflow statement, and financial journal that you may want to take into consideration. Register with us to check it out. More…
Risk Rating Analysis
Star Chart Analysis
Milestone Pharmaceuticals Inc is in competition with PhaseBio Pharmaceuticals Inc, Xeris Biopharma Holdings Inc, and VYNE Therapeutics Inc. All four companies are working to develop new treatments for cardiovascular diseases. Milestone Pharmaceuticals Inc is ahead of its competitors in terms of clinical development and commercialization of its products.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in the United States. The company’s key products are Jakafi and Iclusig. Jakafi is approved for the treatment of myelofibrosis and polycythemia vera, and Iclusig is approved for the treatment of chronic myeloid leukemia. Incyte has a market cap of $9.82 million and a return on equity of 58.1%. The company’s products are sold in over 50 countries worldwide.
– Xeris Biopharma Holdings Inc ($NASDAQ:XERS)
Xeris Biopharma Holdings Inc is a biopharmaceutical company that focuses on the development and commercialization of its innovative therapies. The company’s products are based on its proprietary technology platforms, which include XeriSol, XeriJect, and XeriFuse. Xeris’ products are designed to improve patient outcomes and reduce healthcare costs. The company’s most advanced product candidates are XeriSol for the treatment of diabetes, XeriJect for the treatment of cancer, and XeriFuse for the treatment of autoimmune diseases.
– VYNE Therapeutics Inc ($NASDAQ:VYNE)
VYNE Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel solutions for patients with cardiovascular disease. The company’s lead product candidate is etranexamic acid, which is in Phase III clinical development for the prevention of blood clots in patients undergoing cardiac surgery. VYNE also has a portfolio of early-stage product candidates in various stages of development.
The company’s market cap is 14.12M as of 2022 and its ROE is -78.86%. The company’s focus on developing novel solutions for patients with cardiovascular disease makes it an attractive investment opportunity in the healthcare sector.
MILESTONE PHARMACEUTICALS recently reported their financial results for the second quarter of FY2023, ending on June 30th, 2023. Total revenue for the quarter was USD 0.0 million, a decrease from the prior year’s figure of 0.0 million. The company’s reported net income was USD -16.0 million, a decrease from the -16.6 million reported the year before. Despite these financials, the stock price moved up on the same day of the report. Investors should consider the short-term and long-term outlook of MILESTONE PHARMACEUTICALS when deciding whether or not to invest. This includes evaluating current financial performance and potential future growth opportunities.
Additionally, understanding the competitive landscape and regulatory environment in which MILESTONE PHARMACEUTICALS operates is essential in making informed decisions.